Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVTX-002 · 1 trial · 1 indication
Percentage of patients who experience any of the following asthma related events: * ≥6 additional reliever puffs of Short-Acting Beta-Agonist (compared to baseline) in a 24-hour period on 2 consecutive days or, * increase in inhaled corticosteroid dose ≥4 times than the dose at baseline or, * a decrease in peak flow of 30% or more (compared to baseline) on 2 consecutive days of treatment, or * an asthma exacerbation requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days, or * a hospitalization or emergency room visit because of an asthma exacerbation
| Arm | Type | Description |
|---|---|---|
| AVTX-002 | EXPERIMENTAL | Approximately 40 subjects will receive AVTX-002 at a dose of 600 mg three times during the study. |
| Placebo | PLACEBO_COMPARATOR | Approximately 40 subjects will receive placebo sourced as normal saline three times during the study. |
| Name | Type | Description |
|---|---|---|
| AVTX-002 | DRUG | Dose of 600 mg administered subcutaneously three times during the study. |
| Placebo | DRUG | Placebo sourced as normal saline administered subcutaneously three times during the study. |
Inclusion Criteria: * Documented non-eosinophilic asthma diagnosis (\<300 eosinophils/μL). * Symptoms consistent with a diagnosis of asthma that is poorly controlled as determined by an ACQ score ≥ 1.5. * Poorly controlled asthma despite the use of a Long-Acting Beta-Agonists and Inhaled Corticoste...
AVTX-002 is an investigational small molecule being developed for the treatment of poorly controlled non-eosinophilic asthma. It is currently in Phase 2 clinical development and has not been approved by the FDA.
AVTX-002 is being developed by Avalo Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AVTX.
AVTX-002 is in Phase 2 clinical development. A Phase 2 clinical trial evaluating the drug for the treatment of poorly controlled non-eosinophilic asthma has been completed.
AVTX-002 has one completed Phase 2 clinical trial, identified as NCT05288504. This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of AVTX-002 in 91 adult patients with poorly controlled non-eosinophilic asthma in the United States.
AVTX-002 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of poorly controlled non-eosinophilic asthma.